Food intake in lean and obese mice after peripheral administrationof glucagon-like peptide 2

Risultato della ricerca: Articlepeer review

24 Citazioni (Scopus)

Abstract

We investigated the potential anorectic action of peripherally administered glucagon-like peptide 2 (GLP2) in lean anddiet-induced obese (DIO) mice. Mice, fasted for 16 h, were injected i.p. with native GLP2 or [Gly2]GLP2, stable analog of GLP2, before or after GLP2 (3–33), a GLP2 receptor(GLP2R) antagonist, or exendin (9–39), a GLP1R antagonist. Food intake was measured at intervals 1, 2, 4, 8, and 24 hpostinjection. In addition, we tested in lean mice the influence of [Gly2]GLP2 on gastric emptying and the effects of GLP1 alone or in combination with [Gly2]GLP2 on food intake. [Gly2]GLP2 dose dependently and significantly inhibited food intake in lean and DIO mice. The reduction of food intake occurred in the first hour postinjection and it was sustained until 4 h postinjection in lean mice while it was sustained until 2 h postinjection in DIO mice. GLP2 significantly inhibited food intake in both lean and DIO mice but only in the first hour postinjection. The efficiency of [Gly2]GLP2 or GLP2 in suppressing food intake wassignificantly weaker in DIO mice compared with lean animals. The [Gly2]GLP2 anorectic actions were blocked by the GLP2R antagonist GLP2 (3–33) or by the GLP1R antagonist exendin (9–39). The coadministration of[Gly2]GLP2 and GLP1 did not cause additive effects. [Gly2]GLP2 decreased the gastric emptying rate. Results suggest that GLP2 can reduce food intake in mice in the short term, likely acting at a peripheral level. DIO mice are less sensitive to the anorectic effect of the peptide.
Lingua originaleEnglish
pagine (da-a)277-284
Numero di pagine8
RivistaJournal of Endocrinology
Volume213
Stato di pubblicazionePublished - 2012

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Entra nei temi di ricerca di 'Food intake in lean and obese mice after peripheral administrationof glucagon-like peptide 2'. Insieme formano una fingerprint unica.

Cita questo